22 May 2013
Keywords: S*BIO, JAK2 inhibitor, Orphan status, Europe
Article | 19 October 2010
Privately-held Singapore-based S*BIO Pte says that the European Commission has granted orphan drug designation to SB1518, its potent and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 October 2010
21 May 2013
© 2013 thepharmaletter.com